Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02799602 · ClinicalTrials.gov registry record · Phase 3
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,306
- Enrollment target
NCT02799602 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 1,306 participants.
The verdict
NCT02799602, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,306 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.
Interventions
- DRUG Placebo
- DRUG Docetaxel
- DRUG BAY1841788 / darolutamide (ODM-201)
- DRUG Standard ADT (androgen deprivation therapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,306 participants |
| Start Date | 2016-11-30 |
| Est. Completion | 2023-04-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02799602
The ClinicalTrials.gov registry entry for NCT02799602 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02799602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02799602 about?
NCT02799602 is a clinical study titled "Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer". The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.
What is the current status of trial NCT02799602?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,306 participants. The study started on 2016-11-30. Estimated completion is 2023-04-11.
What interventions are being tested in trial NCT02799602?
The interventions under investigation include: Placebo (DRUG), Docetaxel (DRUG), BAY1841788 / darolutamide (ODM-201) (DRUG), Standard ADT (androgen deprivation therapy) (DRUG).
Who is sponsoring clinical trial NCT02799602?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.